# US 2019/0167677 A1 · Method Of Treating Metabolic Disorders And Depression With Dopamine Receptor Agonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0167677 A1
- Document ID: US20190167677A1
- Status: Published application
- Kind: A1
- Application number: 16/270,348
- Filed: 2019-02-07
- Published: 2019-06-06
- Earliest claimed: 2007-06-21
- Assignees: VeroScience LLC
- Applicants: VeroScience LLC
- Inventors: Anthony H. Cincotta
- Web page: https://patentgrep.com/patent/US20190167677A1

## CPC

- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/48: Ergoline derivatives, e.g. lysergic acid, ergotamine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61K 31/609: Amides, e.g. salicylamide {(labetalol, metoclopramide A61K31/166)}
- A61P 25/24: Antidepressants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention relates to methods and formulations for treating metabolic disorders and depression. In some embodiments, the methods comprise administering a dopamine receptor agonist and an anti-depressant.

## Claims

### Claim at position 1

1-16. (canceled)

### Claim 17

A dosage form for administration to patients suffering from obesity or cardiovascular disease and suffering from depression comprising a first active agent and a second active agent, wherein said first active agent is a serotonin enhancing agent, said second active agent is a dopamine agonist, said first active agent is substantially released within 2 hours following administration of said dosage form and said second active agent is released substantially within the period within 2 hours of waking when said dosage is administered at bedtime.

### Claim 18 (depends on 17)

The dosage form of claim 17 wherein the first active agent comprises an antidepressant.

### Claim 19 (depends on 17)

The dosage form of claim 17 wherein the dopamine agonist is an ergot related dopamine D2 agonist.

### Claim 20 (depends on 17)

The dosage form of claim 17 wherein the dopamine agonist is an ergot related dopamine D2 agonist.

### Claim 21 (depends on 17)

The dosage form of claim 17 wherein the dopamine agonist is a DI dopamine agonist.

### Claim 22 (depends on 17)

The dosage form of claim 17 wherein the dopamine agonist is a D2 dopamine agonist.

### Claim 23 (depends on 21)

The dosage form of claim 21 wherein the DI dopamine agonist is SKF 38393.

### Claim 24 (depends on 21)

The dosage form of claim 21 wherein the DI dopamine agonist is apomorphine.

### Claim 25 (depends on 17)

The dosage form of claim 17 wherein the first active agent is a selective serotonin reuptake inhibitor.

### Claim 26 (depends on 17)

The dosage form of claim 17 wherein the selective serotonin reuptake inhibitor is fluoxetine.

### Claim 27 (depends on 22)

The dosage form of claim 22 wherein the D2 dopamine agonist is bromocriptine.

### Claim 28

The method of treating a patient suffering from depression and at least one of obesity or cardiovascular disease which comprises administering to the patient a dosage form comprising a first active agent and a second active agent, wherein said first active agent is a serotonin enhancing agent, said second active agent is a dopamine agonist, said first active agent is substantially released within 2 hours following administration of said dosage form and said second active agent is released substantially within the period within 2 hours of waking when said dosage is administered at bedtime.

### Claim 29 (depends on 28)

The method of claim 28 wherein the dopamine agonist is a D1 dopamine agonist.

### Claim 30 (depends on 28)

The method of claim 28 wherein the dopamine agonist is a D2 dopamine agonist.

### Claim 31 (depends on 30)

The method of claim 30 wherein the D2 dopamine agonist comprises bromocriptine.

### Claim 32 (depends on 29)

The method of claim 29 wherein the D1 dopamine agonist is SKF38393.

### Claim 33 (depends on 29)

The method of claim 29 wherein the D1 dopamine agonist is apomorphine.

### Claim 34 (depends on 28)

The method of claim 28 wherein the serotonin enhancing agent is a selective serotonin reuptake inhibitor.